FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number: 3235-0									
Estimated average burden									
hours per response	e: 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person Ross Leonard S				2. Issuer Name and Ticker or Trading Symbol pSivida Corp. [PSDV]									heck all Di	ship of Reportir applicable) rector ficer (give title	10% (
	(Fir VIDA CO: EASANT S	RP.	/liddle)	3. Date of Earliest Transaction (Month/Day/Year) 03/19/2018									X Officer (give title Street (specify below) See Remarks				
(Street)	RTOWN M	A 0	2472 (ip)	4. If Amendment, Date of Original Filed (Month/Day/Year)									Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction (A) or Disp (Instr. 3, 4 s		posed	l Of (D)	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	(A) or (D)	Price	Reported Transaction (s) (Instr. 3 and 4)	(I) (Instr. 4)			
Common stock			03/19/2018		8			A		10,000	A	\$0.00	10,000	D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date Exe (Month/Day/Year) if a	3A. Deemed Execution Date, if any (Month/Day/Year)	Transaction N Code (Instr. 8) D S A A (A (A (Instr. B (I		of Deri Sec Acq (A) (Disp of (I	oosed D) tr. 3, 4	Expiration	Date Exercisable and xpiration Date lonth/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4		8. Price Derivat Securit (Instr. 5	e of derivative	(I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expira Date	ition	or Nu of	ımber					

Explanation of Responses:

1. On March 19, 2018 (the "NDA Acceptance Date"), the U.S. Food and Drug Administration ("FDA") accepted pSivida Corp.'s (the "Company") new drug application for Durasert 3-year treatment for posterior segment uveitis. As a result, 5,000 shares representing a previously granted performance stock unit award vested on that date. An additional 5,000 shares from this award will vest on the first anniversary of the NDA Acceptance Date, subject to the Reporting Person's continued employment with the Company through the applicable vesting date.

Remarks:

Vice President of Finance and Chief Accounting Officer

/s/ John Mercer, Attorneyin-Fact

03/21/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).